Mireca Medicine is a pre-clinical stage ophthalmology start-up company seated in Tübingen (Germany) aiming to bring its targeted, small molecule drug candidate to patients suffering from previously incurable hereditary retinal diseases. Mireca Medicine is connected to an international research network.
Developing small molecules to treat a broad band of photoreceptor mutations.
Mireca Medicines was founded to continue the R&D work originating from FP7 project DRUGSFORD. All DRUGSFORD consortium members are founding shareholders of Mireca.
From Lund University: Per Ekström, Ophthalmology at the Department of Clinical Sciences.
Portfolio company since 2017.
Portfolio Manager LU Holding:
christine [dot] widstrand [at] innovation [dot] lu [dot] se (Christine Widstrand), phone +46 70 928 63 78